Korean J Urol Oncol.
2021 May;19(2):79-91. 10.22465/kjuo.2021.19.2.79.
An Update of Gonadotropin-Releasing Hormone Antagonists in the Treatment of Advanced Prostate Cancer
- Affiliations
-
- 1Department of Urology, Dankook University College of Medicine, Cheonan, Korea
- KMID: 2516480
- DOI: http://doi.org/10.22465/kjuo.2021.19.2.79
Abstract
- For decades, androgen deprivation therapy (ADT) was the cornerstone treatment for advanced prostate cancer. ADT using gonadotropin-releasing hormone (GnRH) agonist or antagonist acts by blocking the hypothalamic-pituitary-gonadal system with different mechanism. Both injectable GnRH agonist and antagonist are currently used as a standard of care. The novel oral GnRH antagonist has recently approved and it may have a promising alternative to the conventional ADT. This review will focus on the history of drug development, efficacy and safety profiles for GnRH antagonists in patients with prostate cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Current Concepts in Androgen Deprivation Therapy
- Indication of Gonadotropin-Releasing Hormone Agonist: Precocious Puberty or Advanced Puberty?
- Quality of Life in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy
- Response of Human Chorionic Gonadotropin to 6-D-Trp-Gonadotropin-Releasing Hormone and Gonadotropin-Releasing Hormone Stimulation in the Culture Media of Normal Human Placenta of Different Gestational Ages
- The Role of Gonadotropin: Releasing Hormone ( GnRH ) and Its Receptor in the Extrapituitary Tissues
